Pfizer Inc. (NYSE:PFE) Shares Acquired by Ritholtz Wealth Management
Pfizer Inc. (NYSE:PFE) Shares Acquired by Ritholtz Wealth Management
Ritholtz Wealth Management increased its position in Pfizer Inc. (NYSE:PFE – Get Rating) by 22.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 70,807 shares of the biopharmaceutical company's stock after acquiring an additional 12,750 shares during the period. Ritholtz Wealth Management's holdings in Pfizer were worth $3,712,000 at the end of the most recent reporting period.
Ritholtz Wealth Management在提交給美國證券交易委員會的最近一份13F文件中稱，該公司在第二季度增持了輝瑞(紐約證券交易所代碼：PFE-GET評級)的頭寸22.0%。在此期間，該公司額外收購了12,750股票，擁有70,807股這家生物製藥公司的股票。在最近一個報告期結束時，Ritholtz Wealth Management持有的輝瑞股份價值3,712,000美元。
Other large investors have also modified their holdings of the company. Baltimore Washington Financial Advisors Inc. acquired a new stake in shares of Pfizer in the 4th quarter worth about $290,000. Rinkey Investments acquired a new position in Pfizer during the 4th quarter valued at about $32,000. Worth Asset Management LLC acquired a new position in Pfizer during the 1st quarter valued at about $29,000. Bivin & Associates Inc. acquired a new position in Pfizer during the 4th quarter valued at about $37,000. Finally, Stuart Chaussee & Associates Inc. increased its stake in Pfizer by 108.3% during the 1st quarter. Stuart Chaussee & Associates Inc. now owns 625 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 325 shares during the period. Institutional investors and hedge funds own 67.90% of the company's stock.
其他大型投資者也調整了對該公司的持股。巴爾的摩華盛頓金融顧問公司(Baltimore Washington Financial Advisors Inc.)在第四季度增持了輝瑞股份，價值約29萬美元。Rinkey Investments在第四季度收購了輝瑞的一個新頭寸，價值約3.2萬美元。Worth Asset Management LLC在第一季度收購了輝瑞的一個新頭寸，價值約2.9萬美元。Bivin&Associates Inc.在第四季度收購了輝瑞的一個新頭寸，價值約3.7萬美元。最後，Stuart Chaussee&Associates Inc.在第一季度增持了輝瑞108.3%的股份。Stuart Chaussee&Associates Inc.在此期間又購買了325股，現在持有這家生物製藥公司625股股票，價值3.2萬美元。機構投資者和對衝基金持有該公司67.90%的股票。
Pfizer Stock Performance
輝瑞股票表現
Shares of PFE opened at $44.08 on Friday. Pfizer Inc. has a one year low of $40.94 and a one year high of $61.71. The company has a 50-day moving average of $48.24 and a two-hundred day moving average of $50.32. The stock has a market cap of $247.39 billion, a price-to-earnings ratio of 8.63, a PEG ratio of 0.54 and a beta of 0.70. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.42 and a quick ratio of 1.20.
上週五，PFE的股價開盤報44.08美元。輝瑞公司股價一年來最低為40.94美元，一年最高為61.71美元。該公司的50日移動均線切入位在48.24美元，200日移動均線切入位在50.32美元。該股市值為2,473.9億美元，市盈率為8.63倍，市盈率為0.54倍，貝塔係數為0.70。該公司的債務權益比為0.39，流動比率為1.42，速動比率為1.20。
Pfizer Announces Dividend
輝瑞宣佈分紅
The business also recently declared a quarterly dividend, which will be paid on Monday, December 5th. Investors of record on Friday, November 4th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 3.63%. The ex-dividend date of this dividend is Thursday, November 3rd. Pfizer's dividend payout ratio is currently 31.31%.
該公司最近還宣佈了季度股息，將於12月5日(星期一)支付。11月4日(星期五)登記在冊的投資者將獲得每股0.40美元的股息。這意味着年化股息為1.60美元，股息收益率為3.63%。本次股息除息日期為11月3日(星期四)。輝瑞的派息比率目前為31.31%。
Analysts Set New Price Targets
分析師設定新的價格目標
Several equities analysts have commented on the stock. UBS Group set a $59.00 target price on shares of Pfizer in a research note on Thursday, September 1st. Morgan Stanley lowered their target price on shares of Pfizer from $52.00 to $49.00 and set an "equal weight" rating on the stock in a research note on Friday, July 8th. SVB Leerink lowered their target price on shares of Pfizer from $55.00 to $53.00 and set a "market perform" rating on the stock in a research note on Friday, July 29th. Barclays set a $50.00 price objective on shares of Pfizer in a research note on Thursday, September 1st. Finally, JPMorgan Chase & Co. set a $57.00 price objective on shares of Pfizer in a research note on Tuesday, June 28th. Nine equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $57.00.
幾位股票分析師對該股發表了評論。瑞銀集團在9月1日週四的一份研究報告中為輝瑞股票設定了59.00美元的目標價。摩根士丹利在7月8日(週五)的一份研究報告中將輝瑞股票的目標價從52.00美元下調至49.00美元，並對該股設定了“同等權重”的評級。SVB Leerink在7月29日週五的一份研究報告中將輝瑞股票的目標價從55.00美元下調至53.00美元，並對該股設定了“市場表現”評級。巴克萊在9月1日週四的一份研究報告中為輝瑞股票設定了50.00美元的目標價。最後，摩根大通在6月28日週二的一份研究報告中為輝瑞的股價設定了57.00美元的目標價。9位股票研究分析師對該股的評級為持有，10位分析師給出了買入評級，一位分析師給出了強烈的買入評級。根據MarketBeat.com的數據，該股目前的共識評級為“適度買入”，共識目標價為57.00美元。
Pfizer Profile
輝瑞簡介
(Get Rating)
(獲取評級)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
輝瑞在全球發現、開發、製造、營銷、分銷和銷售生物製藥產品。該公司在不同的治療領域提供藥物和疫苗，包括Premarin系列和Eiquis品牌的心血管代謝和婦女健康；Ibrance、Xtandi、Sutent、Inlyta、Retacritt、Lorbrena和Braftovi品牌的生物製品、小分子、免疫療法和生物仿製藥；舒必樂、Medrol、Zavicefta、Zithromax、Vfend、Panzyga和Paxlovid品牌的無菌注射和抗感染藥物以及口服新冠肺炎治療。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- 免費獲取StockNews.com關於輝瑞的研究報告
- 華爾街對Datadog的熱情會帶來巨大的收益嗎？
- MarketBeat：回顧一週9/19-9/23
- 為什麼特斯拉的股票保持彈性？
- 需要關注的2只半導體類股走勢逆轉
- 小盤股的裁員是樓市的晴雨表嗎？
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
接受輝瑞日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對輝瑞及相關公司評級的每日簡明摘要。
譯文內容由第三人軟體翻譯。